Navigation Links
Genesis Biopharma Names David Voyticky to Board of Directors
Date:7/18/2011

LOS ANGELES, July 18, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named David Voyticky to its Board of Directors.  Mr. Voyticky is currently President of Miller Energy Resources (NYSE: MILL), an oil and gas exploration company, and has more than 16 years of experience in corporate finance and merger and acquisition consulting. The Genesis Biopharma Board now consists of 6 members, including 4 independent directors.

"David's experience in guiding high growth companies will help us effectively manage our current opportunities," stated Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma. "In addition, as the Company is poised to be a leader in developing new cancer therapies, David's background and expertise in corporate finance and strategic transactions will play an important role in building long term value."

Previously Mr. Voyticky served as a Vice President at the investment banks Goldman Sachs & Co. and Houlihan Lokey Howard & Zukin, where he advised public and private companies on mergers, acquisitions, divestitures, joint ventures, cross-border transactions, and capital-raising activities. He was also a founding partner in Red Mountain Capital Partners, and a partner in Chapman Capital LLC, an activist hedge fund focused on middle market public companies.

Mr. Voyticky received Juris Doctorate and Master's of Business Administration degrees from the University of Michigan, and also holds a Master's in International Policy and Economics from the Ford School at the University of Michigan.  He received his Bachelor of Arts in Philosophy from Pomona College.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted ca
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regenesis Biomedical Announces Additions to Board of Directors
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
7. Genesis Pharmaceuticals Launches New Corporate Website
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Cardiogenesis Reports Third Quarter 2008 Results
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... , July 24, 2014  Now available is a ... Rehealth Regenerative Therapies , located in ... physically active people a new health option: stem ... of age, countless patients suffer from joint and muscle ... as muscle tears, torn rotator cuff, tennis elbow, and ...
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... Distinguished Professor of Engineering at the University of ... solve problems in energy engineering, environmental sustainability and ... zeolites, porous rock with a well-defined, crystalline structure. ... so precisely decided that zeolites can separate molecules ... an angstrom (one-tenth of a nanometer), making them ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2University of Delaware researcher describes new approach for creating organic zeolites 2
... , , WATERTOWN, Mass., Sept. 10 ... breakthrough synthetic chemistry technology announced today that it will ... on the synthesis and antibacterial activity of analogs from ... at the 49th Interscience Conference on Antimicrobial Agents and ...
... STOCKHOLM, September 10 Pergamum AB has announced ... wound healing interests, and create a broad-based therapeutic ... The Pergamum product pipeline consists of five ... Indications covered within the,portfolio include improved wound healing ...
... , , , ... Inc. (PTC) today announced the initiation of a Phase 3 ... in patients with nonsense mutation cystic fibrosis (nmCF). Patients ... conductance regulator (CFTR) protein, a chloride channel necessary for normal ...
Cached Biology Technology:Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6
(Date:7/24/2014)... vision specialist at The University of Texas Health Science ... a grant to help Harris County residents whose vision ... , Even with corrective lenses, many people with low ... a variety of low vision devices, such as telescopes, ... loss. , Iyer is using the three-year, $164,645 SightFirst ...
(Date:7/24/2014)... The Atlantic Forest is a hotspot of biodiversity and ... (frogs, tree-frogs, and toads) in the world. However, current ... past few years has been an increase in the ... with the advance of molecular techniques and availability of ... extensive number of samples for molecular and morphological analysis, ...
(Date:7/24/2014)... N.J. A yearlong study funded by the New ... Edward J. Bloustein School of Planning and Public Policy ... in Sandy-affected towns are skeptical about the likelihood of ... survey respondents, 45 percent indicated they were "pessimistic" or ... by Superstorm Sandy would be rebuilt better than they ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2A tiny new species of frog from Brazil with a heroic name 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... China, September 12, 2013BGI Tech Solutions Co., LTD, ... largest genomics research organization, and South Texas Accelerated ... collaborating on the San Antonio 1000 Cancer Genome ... link genetic alterations that underlie different cancers to ...
... Society of America (ESA) is proud to announce ... Grants. These travel grants, which will help entomology ... in Austin this November are funded by ... Plant-Associated Insects and Nematodes. The grants were created ...
... A tiny number of Asian carp could establish a ... to new research from the University of Waterloo. , Published ... from Professor Kim Cuddington of the Faculty of Science at ... with the introduction of 20 fish into the Great Lakes, ...
Cached Biology News:BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project 2BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project 3Entomological Society of America names winners of 2013 student travel grants 2Entomological Society of America names winners of 2013 student travel grants 3Entomological Society of America names winners of 2013 student travel grants 4Entomological Society of America names winners of 2013 student travel grants 5Entomological Society of America names winners of 2013 student travel grants 6Entomological Society of America names winners of 2013 student travel grants 7Entomological Society of America names winners of 2013 student travel grants 8Tiny number of Asian carp could be big problem for the Great Lakes 2
... Adhesive seal tabs • Reusable, ... can be quickly assembled and disassembled for ... specimens of any thickness with up to ... three chambers per slide. Minimize specimen handling, ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... an aqueous solution that contains a purified ... in a saline solution, pH 6.5 ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ... and stabilizer for biologically active components in ...
Biology Products: